Bomedemstat plus momelotinib for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new combination of two drugs, bomedemstat and momelotinib, for people with myelofibrosis. It aims to see if adding bomedemstat can help when momelotinib alone isn't working well enough, or for those with low blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of primary myelofibrosis or myelofibrosis that came after polycythemia vera or essential thrombocythemia.
- Your myelofibrosis is classified as intermediate-2 or high risk based on a standard scoring system (DIPSS).
- You are either currently taking momelotinib without a good response, or you have low hemoglobin (below 10 g/dL) or low platelet counts (below 100,000 per microliter) and are starting momelotinib.
- You have not taken bomedemstat or other LSD1 inhibitors before.
- You are not using any blood thinners or NSAIDs (like aspirin or ibuprofen) if your platelet count is low.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
This trial checks the long-term safety and continued benefits of bomedemstat for people with certain blood cancers (like essential thrombocythemia and polycythemia vera) who have already been doing well on the drug in an earlier study.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests a combination of two drugs, selinexor and pacritinib, for people with myelofibrosis who have not had previous JAK inhibitor treatment and have low red blood cells (anemia) or low platelets. The goal is to see if these drugs can help improve symptoms and reduce spleen size while being safe for patients with cytopenias.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.